Tag: kite

August 27, 2018

Yescarta (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL

Kite, a Gilead (Nasdaq:GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta (axicabtagene ciloleucel) as a...
June 29, 2018

European CHMP Adopts Positive Opinion for Yescarta (axicabtagene ciloleucel)

Kite, a Gilead Company (Nasdaq:GILD), announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...